May, 2025 | Grand Rounds in Hematology & Oncology, Metastatic Hormone-sensitive Prostate Cancer, Webinars
Dr. Viscuse presents a comprehensive overview of the evolving treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC), emphasizing the importance of personalized therapy. Dr. Viscuse outlines the historical context of androgen deprivation therapy (ADT) as the foundation of advanced prostate cancer treatment. While ADT alone has shown survival benefits, the advent of treatment intensification has significantly altered the therapeutic approach.
May, 2025 | Grand Rounds in Hematology & Oncology, Metastatic Urothelial Carcinoma, Webinars
Dr. Skelton outlines the integration of antibody-drug conjugates (ADCs) into treatment algorithms, particularly the role of enfortumab vedotin (EV) in combination with pembrolizumab, which has demonstrated efficacy in the first-line setting. This is supported by the EV-302 trial, which showed this combination significantly improves overall survival and progression-free survival compared to standard platinum-based chemotherapy, establishing it as a new standard of care.
May, 2025 | Acute Myeloid Leukemia, Grand Rounds in Hematology & Oncology, Webinars
Dr. Garrett-Bakelman proposes that AML relapse is shaped not only by genetic mutations and epigenetic alterations but also by transcriptional regulators that may independently promote tumor fitness and survival. This multifaceted understanding underscores the complexity of AML and the need for diverse therapeutic approaches to improve outcomes for relapsed patients.
May, 2025 | Grand Rounds in Hematology & Oncology, Webinars
Dr. Gehrig discusses the intersection of obesity, hair products, and gynecologic cancer risk, outlining how obesity and the use of chemical hair products are both linked to increased cancer risk, particularly endometrial and breast cancers.
May, 2025 | Grand Rounds in Hematology & Oncology, Webinars
Dr. Fadul highlights that while patients with brain metastases are living longer due to advances in systemic therapy, these treatments often fail to adequately address intracranial disease. Inconsistent access to advanced imaging and care, especially in underserved populations, further compounds disparities in outcomes.
May, 2025 | Grand Rounds in Hematology & Oncology, Webinars
Dr. Varney presents a compelling case for integrating obesity treatment into cancer survivorship care, highlighting that while obesity increases cancer risk, it also influences treatment response, recurrence, and overall survival. She notes that despite its well-established role in cancer outcomes, obesity is often underdiagnosed and undertreated in oncology settings.
May, 2025 | Grand Rounds in Hematology & Oncology, Webinars
Dr. Kaltman frames the talk around persistent disparities in cancer screening, citing data from major reports like the AACR Cancer Disparities Progress Report and the President’s Cancer Panel. Examples include the underutilization of advanced breast imaging among Black women and lower cervical cancer screening rates among LGBTQ+ individuals. These disparities are attributed to multifactorial barriers, including limited access, systemic bias, and inadequacies in current screening guidelines.
May, 2025 | Grand Rounds in Hematology & Oncology, Leukemia, Webinars
Dr. Iacobucci focuses on elucidating the genomic landscape of these malignancies through bulk and single-cell sequencing, identifying genetic drivers, and developing functional models to explore targeted therapies. She highlights the importance of molecular characterization for subclassifying leukemias and informing treatment strategies.
April, 2025 | Grand Rounds in Hematology & Oncology, Webinars
Dr. Dengel provides an overview of the integration of immunotherapy with surgical oncology, focusing on strategies to modulate the tumor microenvironment to enhance immune response in solid tumors.
April, 2025 | Cancer Therapy-Related Cardiac Dysfunction (CTRCD), Grand Rounds in Hematology & Oncology, Webinars
Dr. Abbate defines CTRCD as a decrease in left ventricular ejection fraction (LVEF) of over 10 percentage points to below 50%, regardless of symptoms. This definition encompasses both symptomatic and asymptomatic cases, as well as diastolic dysfunction. With increasing cancer survivorship, CTRCD has become a critical concern, particularly given the potential for delayed cardiac toxicity.
